ClinicalTrials.gg

Program

Dinifedriton

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Overweight · Heart Failure · Diabetes Mellitus, Type 2, led by Rivus Pharmaceuticals.

Furthest: phase 2, since May 2, 20218 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rivus Pharmaceuticals82 open or runningphase 2since May 2, 2021Jul 3, 2020Feb 2027phase 2 · NCT07491458

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2020First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04463017 · 64 enrolled · United States
  2. Jan 8, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04709913 · 30 enrolled · United States
  3. May 2, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04874233 · 80 enrolled · United States
  4. Mar 9, 2022Phase 2 study in Heart Failure With Preserved Ejection FractionNCT05284617 · 67 enrolled · United States
  5. Jul 31, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05979779 · 219 enrolled · United States
  6. Oct 11, 2023Phase 2 study in Diabetes Mellitus, Type 2NCT06104358 · United States
  7. Sep 5, 2025Phase 1 study in OverweightNCT07170189 · 59 enrolled · United States
  8. Mar 2, 2026Phase 2 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07491458 · 180 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07491458

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States2RecruitingFeb 2027180
NCT07170189Overweight · United States1CompletedDec 4, 202559
NCT06104358Diabetes Mellitus, Type 2 · United States2WithdrawnFeb 20250
NCT05979779Non-alcoholic Fatty Liver Disease · United States2Active, not recruitingJan 21, 2025219
NCT05284617Heart Failure With Preserved Ejection Fraction · United States2CompletedMay 24, 202467
NCT04874233Non-alcoholic Fatty Liver Disease · United States2CompletedNov 30, 202180
NCT04709913Non-alcoholic Fatty Liver Disease · United States1CompletedApr 30, 202130
NCT04463017Non-alcoholic Fatty Liver Disease · United States1CompletedMar 30, 202164

How it is read

Names in the registry

  • “HU6”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.